论文部分内容阅读
报告G－CSF在小儿白血病骨髓抑制期的临床应用，共23例（43例次），并设对照组比较。在23例急性白血病患儿，20例为急性淋巴细胞白血病，3例为髓系白血病。结果：骨髓抑制期应用G－CSF组与对照组比较，中性粒细胞绝对值（ANC）恢复到ANC＞1×109／L及血小板（PLT）恢复到PLT＞100X109/L的时间明显缩短（P<0．05）及感染率明显降低（P<0．05），且副反应轻。此结果提示，G－CSF有利于抑制的骨髓的动员及恢复，可提高在强化疗治疗病人的安全性。
The clinical application of G-CSF in myelosuppression of myeloid leukemia was reported in 23 patients (43 cases) and was compared with the control group. In 23 children with acute leukemia, 20 were acute lymphoblastic leukemia and 3 were myeloid leukemia. RESULTS: Compared with the control group, the G-CSF group had a significant decrease in the absolute neutrophil recovery (ANC) to ANC>1×109/L and platelet (PLT) recovery to PLT>100×109/L in the myelosuppressive phase. P<0.05) and infection rate were significantly reduced (P<0.05), and side effects were mild. This result suggests that G-CSF is beneficial to the inhibition of bone marrow mobilization and recovery, and can improve the safety of patients treated with chemotherapy.